Nicole Haynes,Janina Gregorski Nicole Haynes

Significant symptom improvement was seen following the initiation of canakinumab and a brief course of steroids. Glucocorticoids and disease-modifying antirheumatic drugs are the mainstays of treatment.

Martin Brom,Franziska Saxer,Linda Mindeholm et al. Martin Brom et al.

However, in a post-hoc analysis of the large CANTOS trial data (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) testing an anti-IL-1 monoclonal antibody for the secondary prevention of cardiovascular events treatment arms receiving canakinumab demonstrated a substantial reduction in the incidence

Yukako Maeda,Eitaro Hiejima,Kazushi Izawa et al. Yukako Maeda et al.

Cases that responded to tocilizumab and canakinumab were also reported. Earlier diagnosis was associated with higher rates of symptom- or drug-free status at the last follow-up visit.

Michel Moutschen,Cécile Boulanger,Joke Dehoorne et al. Michel Moutschen et al.

This non-interventional study aimed to gain insights into canakinumab use and treatment patterns for these diseases in Belgium....Methods: Between July 1, 2018 and June 30, 2023, this national, non-interventional, retrospective/prospective study enrolled patients aged ≥ 2 years with sJIA, FMF, TRAPS, or MKD/HIDS reimbursed for, and treated with, canakinumab in Belgium....Part 1: retrospective data collection from first canakinumab administration in the initial 6-month reimbursement period until date of study inclusion. Part 2: prospective data collection following study inclusion....Median age at first canakinumab administration was 34.0 years (20.0, 35.0, 37.0, and 42.0 years in sJIA, FMF, TRAPS, and MKD/HIDS, respectively)....Conclusions: These non-interventional study data highlight that canakinumab treatment patterns are generally aligned with the summary of product characteristics (SmPC) and reimbursement criteria in Belgium and further support the well-tolerated safety profile of canakinumab.

Matthias Hepprich,Justus Fischer,Marco Cattaneo et al. Matthias Hepprich et al.

Introduction: Postbariatric hypoglycaemia (PBH) is a complex medical condition with a significant impact on patients' quality of life. The underlying mechanisms remain to be elucidated. We have shown that food ingestion i...

Özlem Satirer,Jörg Henes,Melanie Henes et al. Özlem Satirer et al.

Among the eight maternal exposures, six switched to anakinra, one refused the switch and continued canakinumab, and one had to be switched back to canakinumab due to significant local injection reactions.

Marija Jelusic,Mario Sestan,Natasa Toplak et al. Marija Jelusic et al.

IL-1 inhibitors are available in all countries, but there are differences in practices regarding the licensing and reimbursement of anakinra and canakinumab based on specific indications or diagnoses.

Christopher F Spurney,Jessica Chong,Heather Gordish-Dressman et al. Christopher F Spurney et al.

Methods: We completed an open-label, single dose pilot study of canakinumab 2 mg/kg subcutaneous injection in steroid naïve boys with DMD older than 2 years of age to determine safety and potential serum response biomarkers of efficacy at 4-weeks post treatment....Further studies using canakinumab for a longer treatment period may demonstrate increased benefit.

Naotomo Kambe,Norimitsu Inoue,Yoko Ueki et al. Naotomo Kambe et al.

Methods: During a multicenter, single-arm, open-label, investigator-initiated trial evaluating the efficacy and safety of canakinumab in five Japanese patients with SchS (named the SCan Study after SchS and Canakinumab), based on a similar study conducted in Germany, we measured 32...Results: The improvement in clinical symptoms and quality of life was maintained for 48 weeks following canakinumab treatment....Furthermore, neutrophil counts in peripheral blood decreased following canakinumab administration. Conclusions: This study demonstrated that the primary source of IL1B-expressing cells in SchS is neutrophils....Moreover, canakinumab improves clinical symptoms by regulating neutrophil dynamics in peripheral blood.

Athénaïs Boucly,Stéphane Mitrovic,Maryvonnick Carmagnat et al. Athénaïs Boucly et al.

PAH+ patients more frequently received canakinumab and immunosuppressants than did PAH- patients and had higher frequency of drug reactions to interleukin 1 (IL-1) and/or IL-6 inhibitors (37.5% vs 7.2%, P = .002).